YCBDHIGH SIGNALFINANCIAL10-K

YCBD underwent significant financial restructuring with stockholders' equity surging 268% to $7.2M while total liabilities plummeted 63% to $3.2M, coupled with substantial increases in share count and dividend payments.

The dramatic improvement in the balance sheet structure suggests either a major capital raise, debt restructuring, or asset conversion that fundamentally altered the company's financial position. However, the 70% increase in outstanding shares (from 5.5M to 9.4M) indicates significant dilution occurred to achieve this financial restructuring, which could pressure future earnings per share despite the improved capital structure.

Comparing 2025-12-19 vs 2024-12-18View on EDGAR →
FINANCIAL ANALYSIS

YCBD's financial profile transformed dramatically with stockholders' equity increasing 268% while liabilities decreased 63%, indicating major balance sheet restructuring likely through equity financing given the 70% increase in shares outstanding. Operating performance deteriorated with operating cash flow worsening from -$353K to -$1.5M and dividends paid increasing nearly 600% to $2.6M, creating concerning cash outflows. Despite improved net losses (44% reduction to -$2.0M) and the stronger balance sheet, the combination of share dilution, worsening cash flows, and substantial dividend payments suggests the company may be prioritizing short-term financial stability over operational efficiency and shareholder value preservation.

FINANCIAL STATEMENT CHANGES
Dividends Paid
Cash Flow
+596.4%
$367K$2.6M

Dividend payments increased 596.4% — management confidence in sustained cash generation.

Operating Cash Flow
Cash Flow
-311.7%
-$353K-$1.5M

Operating cash flow fell 311.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
+268%
$2.0M$7.2M

Equity base grew 268% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Interest Expense
P&L
-99.8%
$501K955

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Liabilities
Balance Sheet
-62.9%
$8.6M$3.2M

Liabilities reduced 62.9% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-62.9%
$8.6M$3.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Net Income
P&L
+44.8%
-$3.7M-$2.0M

Net income grew 44.8% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+34.8%
-$3.3M-$2.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
+26.5%
$622K$786K

Receivables grew 26.5% — monitor days sales outstanding for collection efficiency.

Inventory
Balance Sheet
+16.7%
$2.5M$2.9M

Inventory built 16.7% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2025-12-19
PRIOR — 2024-12-18
ADDED
false --09-30 FY 2025 To mitigate the threat to our business, we take a comprehensive approach to cybersecurity risk management.
9,419,410 shares of common stock are issued and outstanding as of December 16, 2025.
In addition, "fiscal 2024" refers to the year ended September 30, 2024, and fiscal 2025 refers to the year ended September 30, 2025.
material risks associated with the ownership of our securities, including; the risks for failing to comply with the continued listing standards of the NYSE American; availability of sufficient liquidity; the designations, rights and preferences of our Series B Convertible Preferred Stock; and dilution upon the issuance of shares of common stock underlying outstanding warrants, options and the Series B Convertible Preferred Stock.
is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds.
+7 more — sign up free →
REMOVED
5,539,124 shares of common stock are issued and outstanding as of December 16, 2024.
In addition, "fiscal 2023" refers to the year ended September 30, 2023, and fiscal 2024 refers to the year ended September 30, 2024.
DESCRIPTION OF BUSINESS Our Company General We own and operate the nationally recognized CBD (cannabidiol) brands cbdMD and Paw CBD as well as our ATRx Labs brand of functional mushrooms.
We believe that we are an industry leader producing and distributing dietary supplements and topical products, with an initial focus on hemp derived products including broad spectrum CBD products and full spectrum CBD products.
Our mission is to identify and formulate products with novel, compelling ingredients and blends to enhance our customer s overall quality of life while bringing education, awareness and accessibility of high quality and effective products to all.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →